Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes

Completed

• Conditions: Acute Myeloid Leukemia

• Registration Number: NCT05057299
• Lead Sponsor: King Hussein Cancer Center

Brief Summary

Patients with extramedullary leukemia were identified over 10 years (January 2003 to September 2019). Clinicopathological,genetic-molecular features were identified and survival outcomes were studied and analyzed.

Detailed Description

We retrospectively collected patients demographics ,including clinicopathological and genetic-molecular parameters in patients with extramedullary leukemia between January 2003 till September 2019 from King Hussein cancer center(KHCC) electronic medical records. All potential prognostic factors were identified and compared with worldwide data published previously. Treatment and survival outcomes were studies and analyzed.

Primary endpoint : Overall survival (OS).

Secondary endpoint :

* Progression Free Survival (PFS).

* incidence of extramedullary leukemia.

Study Timeline

• Study Start: 2020-10-01
• Primary Completion: 2021-01-01
• Study Completion: 2021-01-01
• Status Verified: 2021-09
• Study First Submitted: 2021-09-02
• Study First Submitted QC: 2021-09-15
• Last Update Submitted: 2021-09-15
• Study First Posted: 2021-09-27
• Last Update Posted: 2021-09-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Adult subjects aged ≥18 year and up to 75 years
• Male and females.
• Initially diagnosed and treated with extramedullary leukemia at KHCC and followed till last encounter.
• Patients, who underwent an allogeneic stem cell transplant.
• Period January 2003-September 2019

Exclusion Criteria

• Pediatric patients <18 year of age
• Patients, who lost their follow up within study period.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival (OS),	"4 year, year 4"	To calculate the median and estimated 4-year overall survival

Secondary Outcome Measures

Name	Time	Method
Progression-Free Survival	"4 year, year 4"	To calculate the median and estimated 4-year PFS

Trial Locations

Locations (1)

King Hussein Cancer Center; 🇯🇴 Amman, Jordan